In addition, the ASL-MRI method established in our laboratory and others can be used to assess the improvement of blood-brain barrier in AD patients treated with P2Y1-shRNA AAV, for the purpose of monitoring the therapeutic effect of P2Y1-shRNA AAV on AD [42, 43]. The gene discussed is P2RY1; the disease is Alzheimer disease.